Enfortumab – Uses, Dosage, Side Effects, Interaction Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers.[rx] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link.[rx] It is similar to brentuximab vedotin, another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [rx] and it was first approved for use in the United States in December 2019 under the brand name PadcevTM.[rx] Enfortumab vedotin was later approved by the European Commission on April 13, 2022.[rx] Mechanism of action Enfortumab vedotin is an antibody-drug conjugate comprised of multiple components.[rx] It contains a fully human monoclonal antibody directed against Nectin-4, an extracellular adhesion protein that is highly expressed in urothelial cancers,1 attached to a chemotherapeutic microtubule-disrupting agent, monomethyl auristatin E (MMAE). These two components are joined via a protease-cleavable linker. Enfortumab vedotin binds to cells expressing Nectin-4 and the resulting enfortumab-Nectin-4 complex is internalized into the cell. Once inside the cell, MMAE is released from enfortumab vedotin via proteolytic cleavage and goes on to disrupt the microtubule network within the cell, arresting the cell cycle and ultimately inducing apoptosis.[rx] Enfortumab vedotin is an anti-cancer agent that destroys tumor cells by inhibiting their ability to replicate.[rx] Patients with moderate to severe hepatic impairment should not use enfortumab vedotin – although it has not been studied in this population, other MMAE-containing antibody-drug conjugates have demonstrated increased rates of adverse effects in patients with moderate-severe hepatic impairment.[rx] Enfortumab vedotin may also cause significant hyperglycemia leading, in some cases, to diabetic ketoacidosis, and should not be administered to patients with a blood glucose level >250 mg/dl.[rx] Indications Enfortumab vedotin is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.[rx,rx] Enfortumab vedotin is an antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer. For locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting Locally Advanced Urothelial Cancer Metastatic Urothelial Cancer Use in Cancer Enfortumab vedotin-ejfv is approved to treat adults with: Urothelial cancer (a type of cancer in the bladder or urinary tract) that has spread or cannot be removed by surgery. It is used in: Patients who have received platinum chemotherapy and immunotherapy. Patients who have received at least one other type of treatment and cannot receive cisplatin. Enfortumab vedotin-ejfv is also being studied in the treatment of other types of cancer. Contraindications diabetes a painful condition that affects the nerves in the legs and arms called peripheral neuropathy high blood sugar pregnancy a patient who is producing milk and breastfeeding Dosage Strengths: ejfv 20 mg; ejfv 30 mg Urothelial Carcinoma 1.25 mg/kg (up to a maximum of 125 mg for patients 100 kg or greater) IV over 30 minutes on Days 1, 8. and 15 of a 28-day cycle until disease progression or unacceptable toxicity Dose Adjustments RECOMMENDED DOSE REDUCTION SCHEDULE: Starting dose: 1.25 mg/kg up to 125 mg First dose reduction: 1 mg/kg up to 100 mg Second dose reduction: 0.75 mg/kg up to 75 mg Third dose reduction: 0.5 mg/kg up to 50 mg DOSE MODIFICATIONS: HYPERGLYCEMIA: Blood glucose greater than 250 mg/dL: Withhold this drug until elevated blood glucose has improved to 250 mg/dL or less then resume therapy at the same dose level. PERIPHERAL NEUROPATHY: Grade 2: Withhold until Grade 1 or less, then resume therapy at the same dose level (if first occurrence); for a recurrence, withhold until Grade 1 or less then, resume therapy reduced by one dose level. Grade 3 or greater: Permanently discontinue this drug. SKIN REACTIONS: Grade 3 (severe): Withhold this drug until Grade 1 or less, then resume therapy at the same dose level or consider dose reduction by one dose level. Grade 4 or recurrent Grade 3: Permanently discontinue this drug. OTHER NONHEMATOLOGIC TOXICITY: Grade 3: Withhold this drug until Grade 1 or less, then resume therapy at the same dose level or consider dose reduction by one dose level. Grade 4: Permanently discontinue this drug. HEMATOLOGIC TOXICITY: Grade 3 or 3 thrombocytopenia: Withhold this drug until Grade 1 or less, then resume therapy at the same dose level or consider dose reduction by one dose level. Grade 4 thrombocytopenia: Withhold until Grade 1 or less, then reduce dose by one dose level or discontinue therapy. Administration advice: After reconstitution, immediately administer the infusion IV over 30 minutes. If the infusion is not administered immediately, the prepared infusion bag should not be stored longer than 8 hours at 2C to 8C (36 F to 46 F). NOTE: Do not freeze. Do not administer this drug as an IV push or bolus. Do not mix this drug with, or administer it as an infusion with, other medicinal products. Side Effects The Most Common diarrhea vomiting nausea loss of appetite weight loss taste changes hair loss dry skin shortness of breath trouble breathing cough pale skin skin redness, swelling, fever, or pain at the injection site blurred vision, loss of vision, eye pain or redness, or other visual changes numbness, burning or tingling in hands or feet muscle weakness extreme tiredness or lack of energy More common Blurred vision burning, dry, or itching eyes burning, numbness, tingling, or painful sensations discharge, excessive tearing dry eyes dry mouth eye redness, irritation, or pain flushed, dry skin fruit-like breath odor increased hunger increased thirst increased urination lack or loss of strength nausea rash with flat lesions or small raised lesions on the skin redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid stomach pain sweating trouble breathing unexplained weight loss unsteadiness or awkwardness unusual tiredness or weakness vomiting weakness in the arms, hands, legs, or feet Rare Chest pain chills cough fever a general feeling of discomfort or illness thickening of bronchial secretions Blistering, peeling, or loosening of the skin diarrhea itching joint or muscle pain red irritated eyes red skin lesions, often with a purple center redness, tenderness, itching, burning, or peeling of the skin sore throat sores, ulcers, or white spots in the mouth or on the lips Change in taste cracks in the skin decreased appetite dry skin hair loss or thinning of the hair loss of heat from the body loss of taste nausea painful blisters on the trunk of the body red, swollen skin redness, swelling, or pain of the skin scaling of the skin on the hands and feet skin blisters tingling of the hands and feet ulceration of the skin vomiting Pain, redness, or swelling at the injection site Drug Interactions DRUG INTERACTION Abametapir The serum concentration of Enfortumab vedotin can be increased when it is combined with Abametapir. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Enfortumab vedotin. Abrocitinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Abrocitinib. Afatinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Afatinib. Ambrisentan The serum concentration of Enfortumab vedotin can be increased when it is combined with Ambrisentan. Amiodarone The serum concentration of Enfortumab vedotin can be increased when it is combined with Amiodarone. Amprenavir The serum concentration of Enfortumab vedotin can be increased when it is combined with Amprenavir. Apalutamide The serum concentration of Enfortumab vedotin can be decreased when it is combined with Apalutamide. Apixaban The serum concentration of Enfortumab vedotin can be increased when it is combined with Apixaban. Aprepitant The metabolism of Enfortumab vedotin can be decreased when combined with Aprepitant. Arsenic trioxide The serum concentration of Enfortumab vedotin can be increased when it is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Articaine. Asciminib The serum concentration of Enfortumab vedotin can be increased when it is combined with Asciminib. Asunaprevir The serum concentration of Enfortumab vedotin can be increased when it is combined with Asunaprevir. Atazanavir The serum concentration of Enfortumab vedotin can be increased when it is combined with Atazanavir. Avanafil The serum concentration of Avanafil can be increased when it is combined with Enfortumab vedotin. Avatrombopag The serum concentration of Enfortumab vedotin can be increased when it is combined with Avatrombopag. Axitinib The serum concentration of Axitinib can be increased when it is combined with Enfortumab vedotin. Belantamab The serum concentration of Belantamab mafodotin can be increased when it is combined with Enfortumab vedotin. Belinostat The serum concentration of Enfortumab vedotin can be increased when it is combined with Belinostat. Belumosudil The serum concentration of Enfortumab vedotin can be increased when it is combined with Belumosudil. Bendamustine The serum concentration of Bendamustine can be increased when it is combined with Enfortumab vedotin. Benzocaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Benzyl alcohol. Berotralstat The metabolism of Enfortumab vedotin can be decreased when combined with Berotralstat. Betrixaban The serum concentration of Enfortumab vedotin can be increased when it is combined with Betrixaban. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Enfortumab vedotin. Bisoprolol The serum concentration of Enfortumab vedotin can be increased when it is combined with Bisoprolol. Boceprevir The serum concentration of Enfortumab vedotin can be increased when it is combined with Boceprevir. Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Enfortumab vedotin. Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Enfortumab vedotin. Brentuximab The serum concentration of Brentuximab vedotin can be increased when it is combined with Enfortumab vedotin. Bupivacaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Butamben. Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Enfortumab vedotin. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Enfortumab vedotin. Canagliflozin The serum concentration of Enfortumab vedotin can be increased when it is combined with Canagliflozin. Capmatinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Capsaicin. Carbamazepine The metabolism of Enfortumab vedotin can be increased when combined with Carbamazepine. Carfilzomib The serum concentration of Enfortumab vedotin can be increased when it is combined with Carfilzomib. Carvedilol The serum concentration of Enfortumab vedotin can be increased when it is combined with Carvedilol. Cenobamate The serum concentration of Enfortumab vedotin can be decreased when it is combined with Cenobamate. Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Enfortumab vedotin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Chloroprocaine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Cinchocaine. Ciprofloxacin The metabolism of Enfortumab vedotin can be decreased when combined with Ciprofloxacin. Clarithromycin The serum concentration of Enfortumab vedotin can be increased when it is combined with Clarithromycin. Clobazam The serum concentration of Enfortumab vedotin can be increased when it is combined with Clobazam. Clofazimine The serum concentration of Enfortumab vedotin can be increased when it is combined with Clofazimine. Clomifene The serum concentration of Enfortumab vedotin can be increased when it is combined with Clomifene. Clozapine The metabolism of Enfortumab vedotin can be decreased when combined with Clozapine. Cobicistat The serum concentration of Enfortumab vedotin can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Enfortumab vedotin. Cocaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Cocaine. Colchicine The serum concentration of Enfortumab vedotin can be increased when it is combined with Colchicine. Conivaptan The serum concentration of Enfortumab vedotin can be increased when it is combined with Conivaptan. Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Enfortumab vedotin. Crizotinib The metabolism of Enfortumab vedotin can be decreased when combined with Crizotinib. Curcumin The serum concentration of Enfortumab vedotin can be increased when it is combined with Curcumin. Cyclosporine The metabolism of Enfortumab vedotin can be decreased when combined with Cyclosporine. Dabigatran etexilate The serum concentration of Enfortumab vedotin can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Enfortumab vedotin can be decreased when it is combined with Dabrafenib. Daclatasvir The serum concentration of Enfortumab vedotin can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Dacomitinib. Dactinomycin The serum concentration of Dactinomycin can be increased when it is combined with Enfortumab vedotin. Danazol The serum concentration of Enfortumab vedotin can be increased when it is combined with Danazol. Daptomycin The serum concentration of Enfortumab vedotin can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Enfortumab vedotin. Darolutamide The serum concentration of Enfortumab vedotin can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Enfortumab vedotin can be increased when it is combined with Darunavir. Dasabuvir The serum concentration of Enfortumab vedotin can be increased when it is combined with Dasabuvir. Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Enfortumab vedotin. Delavirdine The serum concentration of Enfortumab vedotin can be increased when it is combined with Delavirdine. Desvenlafaxine The metabolism of Enfortumab vedotin can be decreased when combined with Desvenlafaxine. Dexamethasone The metabolism of Enfortumab vedotin can be increased when combined with Dexamethasone. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Enfortumab vedotin. Digoxin The serum concentration of Digoxin can be increased when it is combined with Enfortumab vedotin. Diltiazem The metabolism of Enfortumab vedotin can be decreased when combined with Diltiazem. Diosmin The serum concentration of Enfortumab vedotin can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Diphenhydramine. Dolutegravir The serum concentration of Enfortumab vedotin can be increased when it is combined with Dolutegravir. Dronedarone The metabolism of Enfortumab vedotin can be decreased when combined with Dronedarone. Duvelisib The serum concentration of Enfortumab vedotin can be increased when it is combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Dyclonine. Econazole The serum concentration of Enfortumab vedotin can be increased when it is combined with Econazole. Edoxaban The serum concentration of Enfortumab vedotin can be increased when it is combined with Edoxaban. Efavirenz The serum concentration of Enfortumab vedotin can be increased when it is combined with Efavirenz. Elagolix The serum concentration of Enfortumab vedotin can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Enfortumab vedotin can be increased when it is combined with Elbasvir. Eliglustat The serum concentration of Enfortumab vedotin can be increased when it is combined with Eliglustat. Elvitegravir The serum concentration of Enfortumab vedotin can be increased when it is combined with Elvitegravir. Enasidenib The serum concentration of Enfortumab vedotin can be increased when it is combined with Enasidenib. Entrectinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Entrectinib. Enzalutamide The serum concentration of Enfortumab vedotin can be decreased when it is combined with Enzalutamide. Erdafitinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Erdafitinib. Ergotamine The serum concentration of Enfortumab vedotin can be increased when it is combined with Ergotamine. Ertugliflozin The serum concentration of Enfortumab vedotin can be increased when it is combined with Ertugliflozin. Erythromycin The metabolism of Enfortumab vedotin can be decreased when combined with Erythromycin. You Might Also Read Plantago Insularis Seed - Uses, Dosage, Side Effects Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Enfortumab vedotin. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Etidocaine. Etoposide The serum concentration of Etoposide can be increased when it is combined with Enfortumab vedotin. Everolimus The serum concentration of Enfortumab vedotin can be increased when it is combined with Everolimus. Favipiravir The serum concentration of Enfortumab vedotin can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Fedratinib. Fexofenadine The serum concentration of Enfortumab vedotin can be increased when it is combined with Fexofenadine. Flibanserin The serum concentration of Enfortumab vedotin can be increased when it is combined with Flibanserin. Fluconazole The metabolism of Enfortumab vedotin can be decreased when combined with Fluconazole. Fluvoxamine The metabolism of Enfortumab vedotin can be decreased when combined with Fluvoxamine. Fosnetupitant The metabolism of Enfortumab vedotin can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Enfortumab vedotin can be increased when combined with Fosphenytoin. Fostemsavir The serum concentration of Enfortumab vedotin can be increased when it is combined with Fostemsavir. Fusidic acid The metabolism of Enfortumab vedotin can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Futibatinib can be increased when it is combined with Enfortumab vedotin. Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Enfortumab vedotin. Gilteritinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Gilteritinib. Glasdegib The serum concentration of Enfortumab vedotin can be increased when it is combined with Glasdegib. Glecaprevir The serum concentration of Enfortumab vedotin can be increased when it is combined with Glecaprevir. Grazoprevir The serum concentration of Enfortumab vedotin can be increased when it is combined with Grazoprevir. Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Enfortumab vedotin. Idelalisib The serum concentration of Enfortumab vedotin can be increased when it is combined with Idelalisib. Imipramine The serum concentration of Imipramine can be increased when it is combined with Enfortumab vedotin. Indacaterol The serum concentration of Enfortumab vedotin can be increased when it is combined with Indacaterol. Indinavir The serum concentration of Enfortumab vedotin can be increased when it is combined with Indinavir. Inotuzumab The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Enfortumab vedotin. Isavuconazole The serum concentration of Enfortumab vedotin can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Enfortumab vedotin can be increased when it is combined with Isavuconazonium. Isoniazid The metabolism of Enfortumab vedotin can be decreased when combined with Isoniazid. Isradipine The metabolism of Enfortumab vedotin can be decreased when combined with Isradipine. Istradefylline The serum concentration of Enfortumab vedotin can be increased when it is combined with Istradefylline. Itraconazole The serum concentration of Enfortumab vedotin can be increased when it is combined with Itraconazole. Ivacaftor The serum concentration of Enfortumab vedotin can be increased when it is combined with Ivacaftor. Ivosidenib The metabolism of Enfortumab vedotin can be increased when combined with Ivosidenib. Ixabepilone The serum concentration of Enfortumab vedotin can be increased when it is combined with Ixabepilone. Ketoconazole The serum concentration of Enfortumab vedotin can be increased when it is combined with Ketoconazole. Lapatinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Enfortumab vedotin. Lasmiditan The serum concentration of Enfortumab vedotin can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Enfortumab vedotin can be increased when it is combined with Ledipasvir. Lefamulin The serum concentration of Enfortumab vedotin can be increased when it is combined with Lefamulin. Lemborexant The serum concentration of Enfortumab vedotin can be increased when it is combined with Lemborexant. Lenvatinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Lenvatinib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Levobupivacaine. Levoketocona The serum concentration of Enfortumab vedotin can be increased when it is combined with Levoketoconazole. Lidocaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Lidocaine. Linagliptin The metabolism of Enfortumab vedotin can be decreased when combined with Linagliptin. Lomitapide The serum concentration of Enfortumab vedotin can be increased when it is combined with Lomitapide. Lonafarnib The serum concentration of Enfortumab vedotin can be increased when it is combined with Lonafarnib. Loncastuximab The serum concentration of Loncastuximab tesirine can be increased when it is combined with Enfortumab vedotin. Loperamide The serum concentration of Enfortumab vedotin can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Enfortumab vedotin can be increased when it is combined with Lopinavir. Lovastatin The metabolism of Enfortumab vedotin can be decreased when combined with Lovastatin. Loxapine The serum concentration of Enfortumab vedotin can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Enfortumab vedotin can be decreased when it is combined with Lumacaftor. Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Enfortumab vedotin. Mannitol The serum concentration of Enfortumab vedotin can be increased when it is combined with Mannitol. Maribavir The serum concentration of Enfortumab vedotin can be increased when it is combined with Maribavir. Mavacamten The serum concentration of Enfortumab vedotin can be decreased when it is combined with Mavacamten. Mefloquine The serum concentration of Enfortumab vedotin can be increased when it is combined with Mefloquine. Meloxicam The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Meloxicam. Mepivacaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Mepivacaine. Methimazole The serum concentration of Enfortumab vedotin can be increased when it is combined with Methimazole. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Enfortumab vedotin. Methylene blue The serum concentration of Enfortumab vedotin can be increased when it is combined with Methylene blue. Metreleptin The metabolism of Enfortumab vedotin can be increased when combined with Metreleptin. Miconazole The metabolism of Enfortumab vedotin can be decreased when combined with Miconazole. Midostaurin The serum concentration of Enfortumab vedotin can be increased when it is combined with Midostaurin. Mifepristone The serum concentration of Enfortumab vedotin can be increased when it is combined with Mifepristone. Milnacipran The metabolism of Enfortumab vedotin can be decreased when combined with Milnacipran. Mirabegron The serum concentration of Enfortumab vedotin can be increased when it is combined with Mirabegron. Mitapivat The serum concentration of Enfortumab vedotin can be increased when it is combined with Mitapivat. Mitotane The metabolism of Enfortumab vedotin can be increased when combined with Mitotane. Morphine The serum concentration of Enfortumab vedotin can be increased when it is combined with Morphine. Naloxone The serum concentration of Enfortumab vedotin can be increased when it is combined with Naloxone. Nefazodone The serum concentration of Enfortumab vedotin can be increased when it is combined with Nefazodone. Nelfinavir The serum concentration of Enfortumab vedotin can be increased when it is combined with Nelfinavir. Neratinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Neratinib. Netupitant The metabolism of Enfortumab vedotin can be decreased when combined with Netupitant. Nicardipine The metabolism of Enfortumab vedotin can be decreased when combined with Nicardipine. Nilotinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Nilotinib. Nilvadipine The metabolism of Enfortumab vedotin can be decreased when combined with Nilvadipine. Nintedanib The serum concentration of Enfortumab vedotin can be increased when it is combined with Nintedanib. Norgestimate The serum concentration of Enfortumab vedotin can be increased when it is combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Enfortumab vedotin. Omadacycline The serum concentration of Enfortumab vedotin can be increased when it is combined with Omadacycline. Ombitasvir The serum concentration of Enfortumab vedotin can be increased when it is combined with Ombitasvir. Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Enfortumab vedotin. Oxetacaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Oxybuprocaine. Pacritinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Enfortumab vedotin can be increased when it is combined with Palbociclib. Paliperidone The serum concentration of Enfortumab vedotin can be increased when it is combined with Paliperidone. Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Enfortumab vedotin. Paritaprevir The serum concentration of Enfortumab vedotin can be increased when it is combined with Paritaprevir. Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Enfortumab vedotin. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Enfortumab vedotin. Pentobarbital The metabolism of Enfortumab vedotin can be increased when combined with Pentobarbital. Phenobarbital The metabolism of Enfortumab vedotin can be increased when combined with Phenobarbital. You Might Also Read Ivermectin Dosage, Side Effects, Interactions Phenol The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Phenol. Phenytoin The metabolism of Enfortumab vedotin can be increased when combined with Phenytoin. Pibrentasvir The serum concentration of Enfortumab vedotin can be increased when it is combined with Pibrentasvir. Pitolisant The serum concentration of Enfortumab vedotin can be decreased when it is combined with Pitolisant. Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Enfortumab vedotin. Ponatinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Ponatinib. Posaconazole The serum concentration of Enfortumab vedotin can be increased when it is combined with Posaconazole. Pralsetinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Pramocaine. Pravastatin The serum concentration of Enfortumab vedotin can be increased when it is combined with Pravastatin. Prednisolone The serum concentration of Prednisolone phosphate can be increased when it is combined with Enfortumab vedotin. Prilocaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Prilocaine. Primaquine The metabolism of Enfortumab vedotin can be decreased when combined with Primaquine. Primidone The metabolism of Enfortumab vedotin can be increased when combined with Primidone. Procaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Procaine. Propafenone The serum concentration of Enfortumab vedotin can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Propoxycaine. Quinidine The serum concentration of Enfortumab vedotin can be increased when it is combined with Quinidine. Quinine The serum concentration of Enfortumab vedotin can be increased when it is combined with Quinine. Ranolazine The serum concentration of Enfortumab vedotin can be increased when it is combined with Ranolazine. Regorafenib The serum concentration of Enfortumab vedotin can be increased when it is combined with Regorafenib. Relugolix The serum concentration of Enfortumab vedotin can be increased when it is combined with Relugolix. Reserpine The serum concentration of Enfortumab vedotin can be increased when it is combined with Reserpine. Revefenacin The serum concentration of Enfortumab vedotin can be increased when it is combined with Revefenacin. Ribociclib The serum concentration of Enfortumab vedotin can be increased when it is combined with Ribociclib. Rifampicin The metabolism of Enfortumab vedotin can be increased when combined with Rifampicin. Rifamycin The metabolism of Enfortumab vedotin can be increased when combined with Rifamycin. Rifapentine The metabolism of Enfortumab vedotin can be increased when combined with Rifapentine. Rimegepant The serum concentration of Enfortumab vedotin can be increased when it is combined with Rimegepant. Riociguat The serum concentration of Enfortumab vedotin can be increased when it is combined with Riociguat. Ripretinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Ripretinib. Ritonavir The serum concentration of Enfortumab vedotin can be increased when it is combined with Ritonavir. Rivaroxaban The serum concentration of Enfortumab vedotin can be increased when it is combined with Rivaroxaban. Rolapitant The serum concentration of Enfortumab vedotin can be increased when it is combined with Rolapitant. Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Enfortumab vedotin. Ropivacaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Ropivacaine. Sapropterin The serum concentration of Enfortumab vedotin can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Enfortumab vedotin can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Enfortumab vedotin can be increased when it is combined with Sarecycline. Satralizumab The serum concentration of Enfortumab vedotin can be decreased when it is combined with Satralizumab. Selexipag The serum concentration of Enfortumab vedotin can be increased when it is combined with Selexipag. Selumetinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Selumetinib. Sildenafil The serum concentration of Enfortumab vedotin can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Enfortumab vedotin can be increased when it is combined with Silodosin. Simeprevir The metabolism of Enfortumab vedotin can be decreased when combined with Simeprevir. Simvastatin The serum concentration of Enfortumab vedotin can be increased when it is combined with Simvastatin. Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Enfortumab vedotin. Sitagliptin The serum concentration of Enfortumab vedotin can be increased when it is combined with Sitagliptin. Sofosbuvir The serum concentration of Enfortumab vedotin can be increased when it is combined with Sofosbuvir. Somatrogon The metabolism of Enfortumab vedotin can be increased when combined with Somatrogon. Sorafenib The serum concentration of Enfortumab vedotin can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Enfortumab vedotin can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Enfortumab vedotin can be decreased when it is combined with Sotorasib. St. John’s Wort The metabolism of Enfortumab vedotin can be increased when combined with St. John’s Wort. Stiripentol The serum concentration of Enfortumab vedotin can be increased when it is combined with Stiripentol. Suvorexant The serum concentration of Enfortumab vedotin can be increased when it is combined with Suvorexant. Tacrolimus The serum concentration of Enfortumab vedotin can be increased when it is combined with Tacrolimus. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Enfortumab vedotin. Tamoxifen The serum concentration of Enfortumab vedotin can be increased when it is combined with Tamoxifen. Tazemetostat The serum concentration of Enfortumab vedotin can be increased when it is combined with Tazemetostat. Technetium The serum concentration of Enfortumab vedotin can be increased when it is combined with Technetium Tc-99m sestamibi. Tegaserod The serum concentration of Enfortumab vedotin can be increased when it is combined with Tegaserod. Telaprevir The serum concentration of Enfortumab vedotin can be increased when it is combined with Telaprevir. Telithromycin The serum concentration of Enfortumab vedotin can be increased when it is combined with Telithromycin. Telotristat ethyl The serum concentration of Enfortumab vedotin can be decreased when it is combined with Telotristat ethyl. Temsirolimus The serum concentration of Enfortumab vedotin can be increased when it is combined with Temsirolimus. Tenofovir The serum concentration of Enfortumab vedotin can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Enfortumab vedotin can be increased when it is combined with Tepotinib. Terfenadine The serum concentration of Enfortumab vedotin can be increased when it is combined with Terfenadine. Tetracaine The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Tetracaine. Tezacaftor The serum concentration of Enfortumab vedotin can be increased when it is combined with Tezacaftor. Ticagrelor The serum concentration of Enfortumab vedotin can be increased when it is combined with Ticagrelor. Tipranavir The serum concentration of Enfortumab vedotin can be increased when it is combined with Tipranavir. Tivozanib The serum concentration of Enfortumab vedotin can be increased when it is combined with Tivozanib. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Enfortumab vedotin. Topotecan The serum concentration of Topotecan can be increased when it is combined with Enfortumab vedotin. Toremifene The serum concentration of Enfortumab vedotin can be increased when it is combined with Toremifene. Trastuzumab The serum concentration of Trastuzumab emtansine can be increased when it is combined with Enfortumab vedotin. Trilaciclib The serum concentration of Trilaciclib can be increased when it is combined with Enfortumab vedotin. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Enfortumab vedotin. Troleandomycin The serum concentration of Enfortumab vedotin can be increased when it is combined with Troleandomycin. Tucatinib Tucatinib may decrease the excretion rate of Enfortumab vedotin which could result in a higher serum level. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Enfortumab vedotin. Umbralisib The serum concentration of Enfortumab vedotin can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Enfortumab vedotin can be increased when it is combined with Umeclidinium. Vandetanib The serum concentration of Enfortumab vedotin can be increased when it is combined with Vandetanib. Vardenafil The serum concentration of Enfortumab vedotin can be increased when it is combined with Vardenafil. Velpatasvir The serum concentration of Enfortumab vedotin can be increased when it is combined with Velpatasvir. Vemurafenib The serum concentration of Enfortumab vedotin can be increased when it is combined with Vemurafenib. Venetoclax The metabolism of Enfortumab vedotin can be decreased when combined with Venetoclax. Verapamil The metabolism of Enfortumab vedotin can be decreased when combined with Verapamil. Viloxazine The metabolism of Enfortumab vedotin can be decreased when combined with Viloxazine. Vinblastine The serum concentration of Vinblastine can be increased when it is combined with Enfortumab vedotin. Vincristine The serum concentration of Vincristine can be increased when it is combined with Enfortumab vedotin. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Enfortumab vedotin. Voclosporin The serum concentration of Enfortumab vedotin can be increased when it is combined with Voclosporin. Vorapaxar The serum concentration of Enfortumab vedotin can be increased when it is combined with Vorapaxar. Voriconazole The serum concentration of Enfortumab vedotin can be increased when it is combined with Voriconazole. Voxilaprevir The serum concentration of Enfortumab vedotin can be increased when it is combined with Voxilaprevir. You Might Also Read Dosage of Benzyl Benzoate - Side Effects, Warning Zimelidine The metabolism of Enfortumab vedotin can be decreased when combined with Zimelidine. Ziprasidone The metabolism of Enfortumab vedotin can be decreased when combined with Ziprasidone. Zonisamide The serum concentration of Enfortumab vedotin can be increased when it is combined with Zonisamide. Pregnancy and Lactation US FDA pregnancy category Not Assigned Pregnancy This drug can harm a developing fetus. Adequate methods of contraception should be encouraged. Verify negative pregnancy status in females of reproductive potential prior to initiating therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Advise females of reproductive potential to use effective contraception during therapy and for 2 months after. Advise male patients with female partners of reproductive potential to use effective contraception during therapy and for 4 months after. This drug may impair male fertility. Lactation Use should be avoided. Excreted into human milk: Unknown Excreted into animal milk. Because of the potential for serious adverse reactions in a breastfed child, advise lactating women not to breastfeed during therapy and for at least 3 weeks after. How should this medicine be used? Enfortumab vedotin-ejfv injection comes as a powder to be mixed with liquid and injected intravenously (into a vein) over 30 minutes by a doctor or nurse in a hospital or medical facility. It is usually injected on days 1, 8, and 15 of a 28-day cycle for as long as your doctor recommends that you receive treatment. Your doctor may delay or stop your treatment with enfortumab vedotin-ejfv injection, or treat you with additional medications, depending on your response to the medication and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. What special precautions should I follow? Before receiving enfortumab vedotin-ejfv injection, tell your doctor and pharmacist if you are allergic to enfortumab vedotin-ejfv injection, any other medications, or any of the ingredients in enfortumab vedotin-ejfv injection. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin (Biaxin); idelalisib (Zydelig); indinavir (Crixivan); ketoconazole (Nizoral); nefazodone; nelfinavir (Viracept); ritonavir (Norvir, in Kaletra); or saquinavir (Invirase); and rifampin (Rimactane). Many other medications may also interact with enfortumab vedotin-ejfv, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have or have ever had peripheral neuropathy (a type of nerve damage that causes tingling, numbness, and pain in the hands and feet), diabetes or high blood sugar, lung problems, or liver disease. tell your doctor if you are pregnant, plan to become pregnant, or if you plan to father a child. You or your partner should not become pregnant while you are receiving enfortumab vedotin-ejfv injection. Your doctor may perform a pregnancy test to be sure that you are not pregnant before you receive enfortumab vedotin-ejfv injection. If you are female, you should use birth control during your treatment and for 2 months after your final dose. If you are male, you and your female partner should use birth control during your treatment and for 4 months after your final dose. Talk to your doctor about birth control methods that will work for you. If you or your partner become pregnant while receiving enfortumab vedotin-ejfv injection, call your doctor. Enfortumab vedotin-ejfv injection may harm the fetus. tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving enfortumab vedotin-ejfv injection and for at least 3 weeks after your final dose. you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of receiving enfortumab vedotin-ejfv injection. you should know that you may experience hyperglycemia (increases in your blood sugar) while you are receiving this medication, even if you do not already have diabetes. Tell your doctor immediately if you have any of the following symptoms while you are receiving enfortumab vedotin-ejfv injection: extreme thirst, frequent urination, extreme hunger, blurred vision, or weakness. It is very important to call your doctor as soon as you have any of these symptoms because high blood sugar that is not treated can cause a serious condition called ketoacidosis. Ketoacidosis may become life-threatening if it is not treated at an early stage. Symptoms of ketoacidosis include dry mouth, nausea and vomiting, shortness of breath, breath that smells fruity, and decreased consciousness. you should know that this medication may cause dry eyes and other eye problems, which may be serious. Your doctor may tell you to use artificial tears or lubricant eye drops during your treatment with enfortumab vedotin-ejfv. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s006s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761137s006s008lbl.pdf https://www.cancer.gov/about-cancer/treatment/drugs/enfortumabvedotin-ejfv https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-enfortumab-vedotin-ejfv-metastatic-urothelial-cancer https://pubchem.ncbi.nlm.nih.gov/substance/347911415 https://www.drugs.com/mtm/enfortumab-vedotin.html https://go.drugbank.com/drugs/DB13007 https://www.webmd.com/drugs/2/drug-178507/enfortumab-vedotin-ejfv-intravenous/details/list-contraindications https://www.mayoclinic.org/drugs-supplements/enfortumab-vedotin-ejfv-intravenous-route/description/drg-20479535 https://en.wikipedia.org/wiki/Enfortumab_vedotin https://medlineplus.gov/druginfo/meds/a620005.html Show More